Limits...
Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.

Zhou Y, Bian B, Yuan X, Xie G, Ma Y, Shen L - PLoS ONE (2015)

Bottom Line: The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75).Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90).The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

ABSTRACT

Background: The prognostic value of circulating tumor cells (CTCs) in ovarian cancer has been investigated in previous studies, but the results are controversial. Therefore we performed a meta-analysis to systematically review these data and evaluate the value of CTCs in ovarian cancer.

Materials and methods: A literary search for relevant studies was performed on Embase, Medline and Web of Science databases. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analyses, sensitivity analyses, meta-regression analyses and publication bias were conducted.

Results: This meta-analysis is based on 11 publications and comprises a total of 1129 patients. The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75). Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90). The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

Conclusion: Our study demonstrates that CTC status is associated with OS and PFS/DFS in ovarian cancer.

No MeSH data available.


Related in: MedlinePlus

Begg’s funnel plots of the prognostic role of CTCs in OS.CTCs = circulating tumor cells; OS = overall survival.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476582&req=5

pone.0130873.g008: Begg’s funnel plots of the prognostic role of CTCs in OS.CTCs = circulating tumor cells; OS = overall survival.

Mentions: In order to evaluate the influence of single studies on the pooled HRs, we performed a sensitivity analysis by estimating the average HR in the absence of each study. The results indicated that no individual studies significantly influenced the pooled HRs (Fig 7). Begg’s funnel plot (P = 1, Fig 8) and Egger’s linear regression test (P = 0.806) did not show evidence for publication bias.


Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.

Zhou Y, Bian B, Yuan X, Xie G, Ma Y, Shen L - PLoS ONE (2015)

Begg’s funnel plots of the prognostic role of CTCs in OS.CTCs = circulating tumor cells; OS = overall survival.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476582&req=5

pone.0130873.g008: Begg’s funnel plots of the prognostic role of CTCs in OS.CTCs = circulating tumor cells; OS = overall survival.
Mentions: In order to evaluate the influence of single studies on the pooled HRs, we performed a sensitivity analysis by estimating the average HR in the absence of each study. The results indicated that no individual studies significantly influenced the pooled HRs (Fig 7). Begg’s funnel plot (P = 1, Fig 8) and Egger’s linear regression test (P = 0.806) did not show evidence for publication bias.

Bottom Line: The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75).Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90).The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

ABSTRACT

Background: The prognostic value of circulating tumor cells (CTCs) in ovarian cancer has been investigated in previous studies, but the results are controversial. Therefore we performed a meta-analysis to systematically review these data and evaluate the value of CTCs in ovarian cancer.

Materials and methods: A literary search for relevant studies was performed on Embase, Medline and Web of Science databases. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analyses, sensitivity analyses, meta-regression analyses and publication bias were conducted.

Results: This meta-analysis is based on 11 publications and comprises a total of 1129 patients. The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75). Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90). The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

Conclusion: Our study demonstrates that CTC status is associated with OS and PFS/DFS in ovarian cancer.

No MeSH data available.


Related in: MedlinePlus